Needham Maintains Buy on Avidity Biosciences, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer maintains a Buy rating on Avidity Biosciences (NASDAQ:RNA) and raises the price target from $35 to $46.
June 12, 2024 | 7:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer maintains a Buy rating on Avidity Biosciences and raises the price target from $35 to $46.
The raised price target and maintained Buy rating from a reputable analyst are likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100